A Review on Currently Available Potential Therapeutic Options for COVID-19

Solmaz Ohadian Moghadam
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract: A series of unexplained pneumonia cases currently were first reported in December 2019 in Wuhan, China. Official names have been announced for the virus responsible, previously known as “2019 novel coronavirus” and the diseases it causes are, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19), respectively. Despite great efforts worldwide to control SARS-CoV-2, the spread of the virus has reached a pandemic. Infection prevention and control of this virus is the primary concern of public health officials and professionals. Currently, several therapeutic options for COVID-19 are proposed and vaccine development has been initiated for prevention purposes. In this review, we will discuss the most recent evidence about the current potential treatment options including anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, nucleoside analogs, protease inhibitors, monoclonal antibodies, and convalescent plasma therapy. Some other agents such as vitamin D and melatonin, which were recommended as potential adjuvant treatments for COVID-19 infection are also presented. Moreover, the potential use of convalescent plasma for treatment of COVID-19 infection was described. Furthermore, in the next part of the current review, various vaccination approaches against COVID-19 including whole virus vaccines, recombinant subunit vaccine, DNA vaccines, and mRNA vaccines are discussed.

Keywords: COVID-19, SARS-CoV-2, treatment, vaccine, coronavirus

Introduction
As of December 2019, the seventh member of the human coronavirus family was recognized. Several pneumonia cases of unknown etiology were first reported in December 2019 in Wuhan, China. Subsequent studies were initiated on identification of a causative agent and control of the epidemic. This virus is named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its related disease is named COVID-19. Currently, the outbreak has become a major clinical threat to the general population and health-care workers (HCWs) all over the world. This virus has rapidly spread across China and several other countries. The genetic analyses on 103 publicly available SARS-CoV-2 genomes in a more recent study has shown the evolution of these viruses into two major types (L and S). These two types of SARS-CoV-2 are defined by means of two different SNPs. The expression and distribution of the receptor apparently determine the pathogenic mechanisms of virus as well as probable therapeutic strategies. Angiotensin-converting enzyme 2 (ACE2) is considered as the major determinant of cell tropism and pathogenesis for SARS-CoV-2.
In a latest report, the expression of ACE2 was not significantly different between men and women, Asian and white people, or subgroups aged older and younger than 60 years. This study also did not support smoking as a predisposing factor in men for infection with SARS-CoV-2. The findings of a recent study suggested that elderly patients are more likely to experience disease progression than their younger counterparts.

Impaired immunity can lead to virus dissemination and destruction of the affected tissues, particularly in organs with high ACE2 expression. The damaged cells can induce pulmonary inflammation mainly mediated by pro-inflammatory macrophages and granulocytes. Pulmonary inflammation is the leading cause of life-threatening respiratory condition at the severe stage. Therefore, inflammation suppression should be performed at the time of severe lung damage to manage the symptoms. Studies have reported that ALT, LDH, D-dimer and inflammatory markers including hsCRP and ferritin were significantly higher in severe cases than in moderate cases. In addition, serum concentrations of pro-inflammatory cytokines as well as anti-inflammatory cytokines were enhanced in the majority of severe cases and were markedly higher in severe cases than in moderate cases, suggesting cytokine storm might be associated with disease severity.

The most common symptoms of infection with SARS-CoV-2 which have been reported in various studies include fever, followed by dry cough, fatigue, muscle pain, and dyspnea. Some other symptoms such as expectoration, headaches, hemoptysis, nasal obstruction, runny nose, and other upper respiratory rhinorrhea. Gastrointestinal symptoms (vomiting, and diarrhea) have been reported less frequently. The majority of the children infected with SARS-CoV-2 indicate mild symptoms, without fever or pneumonia, and will recover within one to two weeks. The reasons for mild COVID-19 disease in pediatric patients remains unknown. However, several hypotheses exist including: immune differences between children and adults, and the simultaneous presence of other viruses in the lung mucosa of the young children limiting the SARS-CoV2 growth by direct virus-to-virus competition. Differences in the ACE2 expression could be another possibility for the mild COVID-19 infections in children. Some epidemiological studies have revealed an association between Bacillus Calmette–Guérin (BCG) vaccination and COVID-19 morbidity and mortality. Moreover, the nonspecific beneficial effects of some live vaccines, such as BCG, measles and oral polio vaccines have previously been reported. Therefore, BCG may have the potential to decrease severity of SARS-CoV-2 infection by induction of innate immune memory.

Contemporary diagnostic tests available for SARS-CoV-2 include RT-PCR, real-time RT-PCR, and reverse transcription loop-mediated isothermal amplification (RT-LAMP). Both RT-LAMP and real-time RT-PCR have the same sensitivity.

The first detectible serology marker has been reported, total antibody followed by production of IgM and IgG antibodies, with a median seroconversion time of 11, 12, and 14 days respectively. The findings have suggested that antibody testing in addition to RNA tests can provide significant data for diagnosis of SARS-CoV-2 infection. Furthermore, technologies based on CRISPR-Cas12 have the potential to provide an in situ diagnostic tool for rapid detection of the SARS-CoV-2 virus. Binding of Cas12a to target DNA can be detected by a reporter molecule providing a fluorescence signal emission. Finally, a visual readout is provided using a paper dipstick.

Chest CT is a significant tool for COVID-19 diagnosis in clinical practice. The most frequent finding reported from chest CT is ground glass opacity (GGO), and consolidation, interlobular septal thickening in both lungs has been reported as less frequent. In the primary stages of infection, the total number of the peripheral blood leukocytes is normal or decreased, the lymphocyte count is decreased, and in some cases liver enzymes and myoglobin levels indicate increase. Elevated CRP and erythrocyte sedimentation rate (ESR) are frequent. Lymphopenia, leukopenia, elevated level of aspartate aminotransferase are the most common laboratory findings. Primary plasma levels of Interleukin (IL)-1β, IL-1Ra, IL-7, IL-8, IL-9, IL-10, basic fibroblast growth factors (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon gamma (IFNγ), IP10, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory proteins (MIP)-1A, MIP1B, platelet-derived growth factor (PDGF), and tumor necrosis factor alpha (TNF-α) has been shown to be higher in patients infected with SARS-CoV-2 than in healthy controls.

At the time of writing, no vaccine or antiviral drug is available for COVID-19. Infection prevention and control of this virus is the primary concern of public health officials and professionals. Currently, several therapeutic options for COVID-19 are proposed and vaccine
development has also been initiated for prevention purposes. In this review, we will discuss the most recent evidence about the current potential treatment options, vaccine development, and future perspectives of COVID-19 in order to help tackle the SARS-CoV-2 pandemic challenges.

### Potential Treatment Options of COVID-19

Medications inhibiting viral dissemination and blocking viral replication may decrease the coronavirus-induced direct cytopathic effects. In addition prevention of inflammatory responses by antibodies or compounds neutralizing cytokines or their cognate receptors may reduce virus-mediated immune pathologies. The only treatment currently available for patients with COVID-19 mainly relies on symptomatic treatments as no vaccine has been successfully developed to date. Therefore, effective antiviral therapy and vaccination are under assessment. However, according to the World Health Organization (WHO), empirical antibiotics, antiviral agents, and systemic steroids should be used for treatment of severe cases. A recent descriptive study reported that most of the studied patients have received antiviral agents such as oseltamivir (75 mg orally twice daily), ganciclovir (0.25 g intravenously twice daily) and lopinavir/ritonavir tablets (400/100 mg every 12 h orally). Empiric antimicrobial and antifungal therapy should also be considered for potential bacterial or fungal coinfection. The efficacy or adverse effects of intravenous immunoglobulin and systemic steroids being used in some patients are unclear. Invasive ventilation may be used for patients with refractory hypoxemia. Numerous possible drug candidates have been suggested, including chloroquine, DNA synthesis inhibitors (tenofovir disoproxil and lamivudine), lopinavir/ritonavir (Kaletra R®), nucleoside analogues, neuraminidase inhibitors, remdesivir, and umifenovir (Arbidol R®) as well as Chinese traditional medicines (ShuFeng JieDu or Lianhua Qing-wen capsules).

### Small Molecules

Identification of the key components of the viral infections is a major step for recognizing medications with high target specificity. Viral entry to the cell and replication within the cell can be considered as a target for designing the antiviral drugs. In addition to several antiviral drugs, chemical small-molecule compounds are also expected to have significant inhibitory properties on various key proteins of viruses including SARS-CoV-2. These drugs typically inhibit both viral enzymes such as proteases and components of RNA-dependent RNA polymerase (RdRp). Chymotrypsin-like protease (CLPpro; 3CLp) and papain-like protease (PLpro) are two main proteases essential for cleavage of viral polypeptides into active components which are required for viral replication and maturation. RdRp is an enzyme essential for viral RNA synthesis and catalyzes the replication of RNA. The SARS-CoV-2 host cell entry depends on the interaction between ACE2 as the main receptor and viral spike (S) protein. Inhibition of this interaction may also represent a potential therapeutic strategy against COVID-19. Some studies aim to recognize molecules that inhibit the docking of S protein mediated by receptor-binding domain (RBD) onto cells which express ACE2. A recent study showed that a clinical-grade soluble recombinant human ACE2 (hrsACE2) protein can decrease SARS-CoV-2 recovery from simian Vero E6 cells. In addition, they have demonstrated that infection of kidney organoids and engineered human capillary organoids can be inhibited by hrsACE2. These findings suggest that hrsACE2 can considerably prevent SARS-CoV-2 infection by blocking its entry at the early stage of infection.

Umifenovir (Arbidol™; CAS number: 131707–25-0) is a small molecule with an indole core and inhibits viral entry into host cells through inhibition of viral membrane fusion. It is approved in Russia and China as an antiviral treatment for oral prophylaxis and treatment of influenza infections. A recent clinical pilot trial in China reported viral load reduction and decreased mortality rate in COVID-19 patients received arbidol (400 mg; three times; nine days) as compared to the control group. Moreover, there are ongoing clinical trials evaluating the potential efficacy of arbidol alone or in combination with other drugs such as chloroquine and lopinavir/ritonavir against SARS-CoV-2 infection (NCT04255017, NCT04260594, NCT04273763, NCT04286503).

There are several other small molecules that are considered for use in treatment of COVID-19 infection. In further sections of this review, the other small-molecule drugs will be discussed in their respective categories.

### Anti-inflammatory Drugs

Immense immune response is common against viral infections to control the pathogen and this can lead to extensive...
injury to the host cells. A hyperinflammatory state with extreme release of pro-inflammatory cytokines is the most serious presentation of COVID-19 infection and known as cytokine storm.\(^{42}\) The stimulation of pro-inflammatory cytokines by the virus leads to severe organ injury such as acute respiratory distress syndrome (ARDS).\(^{42,43}\) Initial studies have reported decreased immune cell populations such as lymphocyte subsets (CD4+, CD8+) and natural killer (NK) cells as well as increased cytokines in the course of severe COVID-19 pneumonia.\(^{9,11,44,45}\)

Macrophage activation syndrome as well as elevated levels of ferritin, C-reactive protein (CRP), and cytokines like IL-6, IL-8, IL-1β, and TNF-α has been shown in the primary stage of COVID-19 infection.\(^{46}\) Moreover, a significant escalation in inflammatory monocytes mainly CD14 + IL-1β+ cells at the initial stage of recovery was indicated by single cell sequencing of peripheral blood cells.\(^{47}\) The existence of lymphopenia and lower numbers of CD4 and CD8 T cells has been linked to more severe disease.\(^{48}\) In addition, both increased inflammatory CCL6 + Th17 cells and decreased circulating regulatory T cells has been reported in severe cases.\(^{48,49}\) Lymphopenia, spleen atrophy, and pulmonary macrophage infiltration were observed in later stages of infection and autopsy.\(^{8}\) Complement deposition in pulmonary microvasculature due to initiation of alternative complement pathway activation has been reported in COVID-19 infection as well.\(^{50}\)

Therefore, primary inhibition of inflammatory pathways may be considered as a major therapeutic option,\(^{51}\) and anti-inflammatory medications can be a supportive treatment for COVID-19. Several anti-inflammatory drugs are currently available including nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, chloroquine/hydroxychloroquine, and immunosuppressants to prevent or diminish the progression of inflammation.\(^{52}\)

Moreover, particular anti-inflammatory/immunosuppressive agents such as IL-1 inhibitors (anakinra), IL-6 inhibitors (siltuximab), IL-6 receptor antagonist monoclonal antibodies (tocilizumab, sarilumab), TNF-α inhibitors (adalimumab), and the Janus kinase (JAK) inhibitors (fedratinib, baricitinib)\(^{52}\) are being assessed by ongoing clinical trials. However, there has been inadequate evidence for their effectiveness and safety against SARS-CoV-2 infection (Figure 1).\(^{53,54}\)

However, the dilemma of applying anti-inflammation therapy to COVID-19 patients and using anti-inflammatory/immunosuppressives agents in the presence of an active infection seems to be controversial.\(^{55}\) On the one hand, inflammation control is important to inhibit tissue injury. On the other hand, the anti-inflammation therapy such as corticosteroid may postpone the viral eradication and increase the risk of secondary infection. Although some studies have described the effectiveness of glucocorticoids in the treatment of coronavirus pneumonia (severe acute respiratory syndrome, SARS and Middle East respiratory syndrome, MERS) it remains controversial. Some evidence designated that the advantage of using glucocorticoids is likely outweighed by adverse effects.\(^{54}\) However, several reports have not supported corticosteroid for treatment of COVID-19 lung disease.\(^{56}\) According to insufficient evidence, the temporary WHO guideline does not support using systemic corticosteroids for COVID-19 cases. However, there is evidence proposing that cases on chronic anticytokine management for inflammatory diseases mediated by immune responses are not at a greater risk for worse outcomes from COVID-19 infection.\(^{57}\)

**JAK Inhibitors**

One of the key parts of immunopathology during infection caused by coronaviruses is cytokine and chemokine responses. Increased levels of serum pro-inflammatory cytokines such as IFNγ, TNF-α, IL-2, IL-4, IL-6, IL-7, and IL-10 were described in severe COVID-19 cases and were associated with the severity of disease.\(^{58}\) Numerous cytokines involved in COVID-19 utilize an intracellular signaling pathway mediated by JAKs.\(^{59}\) Baricitinib (brand name Olumiant) is a novel small molecule acting as a JAK inhibitor. It is a food and drug administration (FDA)-approved antirheumatoid arthritis medication which has been suggested as a potential candidate for COVID-19 treatment.\(^{60}\) However, JAK inhibitors can block the production of a variety of inflammatory cytokines including IFN-α, which is essential against viral infection and may not be a suitable option for COVID-19 treatment. There are some recent registered clinical trials of JAK inhibitor ongoing in China (ChiCTR2000030170; ChiCTR2000029580).

**Chloroquine and Hydroxychloroquine**

Chloroquine is used either for prevention and treatment of malaria or for the treatment of rheumatoid arthritis and lupus erythematosus. It has wide antiviral effects through increasing endosomal pH essential for virus entry.\(^{51}\) Chloroquine can lead to inhibition of uncoating as well as modification of posttranslational newly synthesized proteins in several viruses such as HIV. Initial in vivo studies have proposed that the chloroquine alone or in
combination with antiretroviral agents may play a role in COVID-19 treatment. It has shown a potent inhibition effect against SARS-CoV through interfering with ACE2. Moreover, its in vitro activity against SARS, MERS, HIV, Ebola, Hendra, and Nipah viruses has been shown. In China, COVID-19 patients were treated...
with chloroquine to evaluate its effectiveness and safety. Their results indicated that chloroquine prevents the exacerbation of COVID-19. An in vitro study has also indicated high effect of remdesivir and chloroquine combination in COVID-19 control. Guidelines (version 6) for COVID-19 treatment recommends oral administration of chloroquine phosphate at a dose of 500 mg (300 mg for chloroquine) for adults, twice/day (no more than 10 days). Several clinical trials have been registered to evaluate the efficacy and safety of chloroquine in the treatment of COVID-19. A recent clinical trial has reported the short-term efficacy of hydroxychloroquine in the treatment of COVID-19. There are studies that reported the superiority of chloroquine phosphate to the control treatment in prevention from progression of pneumonia, improving pulmonary imaging results, viral clearance, and shortening the disease duration. The results of an open-label nonrandomized clinical trial showed that hydroxychloroquine treatment significantly decreased the viral load in patients with COVID-19 infection. However, these studies have some limitations such as small sample size and debatable methodology.

Some potential adverse effects of chloroquine/hydroxychloroquine include retinopathy, cardiac arrhythmias, and muscle weakness. There are also some reports of otoxicity following treatment with these drugs, which may lead to hearing loss. Currently, there is no strong evidence of beneficial potential of chloroquine/hydroxychloroquine for COVID-19 treatment. However, further preclinical and clinical trials are required to prove their effectiveness and safety.

Phosphodiesterase 4 (PDE4) Inhibitors

The PDE4 expression has been established in several inflammatory cells including neutrophils, monocytes, T cells, and eosinophils. Cyclic adenosine monophosphate (cAMP) as an intracellular regulator has a key role in modulation of cytokine release through the nuclear factor κB (NF-κB) and protein kinase A (PKA) pathway. This leads to inhibition of the main pro-inflammatory cytokines including TNF-α, and the stimulation of the anti-inflammatory IL-10. PDE4 is an enzyme account for the hydrolysis of cAMP and reduces its intracellular levels in inflammatory cells. Thus, inhibition of PDE4 leads to several anti-inflammatory properties in various cells such as neutrophils, macrophages, monocytes, T cells, and B cells.

The PDE4 by modification of the intracellular cAMP levels can regulate both pro- and anti-inflammatory cytokine productions. Higher expression of PDE4 in cases with inflammatory diseases compared to healthy individuals has been shown previously. Inhibitors of PDE4 have been suggested as novel anti-inflammatory treatments used in several inflammatory diseases including rheumatoid arthritis, psoriasis, asthma, and chronic obstructive pulmonary disease (COPD). They effectively suppress pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-2, IL-12, IL-17 and IL-23 in inflammatory cells and also inhibit the reactive oxygen species (ROS) production. IL-17 is a pro-inflammatory cytokine produced by T helper (Th)-17 cells and suggested to have a role in acute pulmonary damage during respiratory viral infections. Therefore, IL-17 has been suggested as a target for management of pulmonary damage during COVID-19 infection.

In addition, in vivo studies on animal models of pulmonary damage injury has shown decreased deposition of pulmonary fibrin and vascular alveolar leakage, as well as improved survival due to the inhibition of PDE4. The use of PDE4 inhibitors leads to not only upstream suppression of several cytokine signaling pathways, but also regulation of the pro-inflammatory/anti-inflammatory equilibrium. Therefore, it has been speculated that PDE4 inhibitors can be considered as potential therapeutic options against COVID-19 infection.

Apremilast (Otezla®) is an oral small molecule belongs to the PDE4 inhibitors. Mugheddu et al. recently reported a 45-year-old obese male with erythrodermic psoriasis who was under treatment with apremilast, has fully recovered from COVID-19 infection. A more recent case report also described a 61-year old male who suffered from moderate psoriasis was receiving apremilast and whose family were diagnosed as being SARS-CoV-2 positive. However, despite his close contact with them, the patient showed no symptoms of COVID-19 infection. The nasopharyngeal swab examination indicated that he was positive for SARS-CoV-2, but the CT results showed no pulmonary changes. These reports may suggest anti-inflammatory effects of apremilast against COVID-19 infection. Therefore, it has been suggested that the use of PDE4 inhibitors before the cytokine storm and in the primary stage of COVID-19 pneumonia may signify an appropriate treatment option. Appropriate clinical trials are required in order to explore the potential therapeutic effects of PDE4 inhibitors as well as other therapeutic options.
Methotrexate

Methotrexate is an immune system suppressant belonging to antimetabolites. A recent study has provided robust reasoning for high-dose methotrexate usage in treatment of inflammatory syndromes mediated by SARS-CoV-2. According to the authors, the major mechanism of action of methotrexate is inhibition of folate-dependent methyl transfer enzymes which interferes with the DNA and RNA synthesis leading to inhibition of cell proliferation particularly in dividing cells. Furthermore, methotrexate has several anti-inflammatory effects. It can affect activated inflammatory T cells which are dividing cells. It also directly binds to high-mobility group box 1 (HMGB1) protein and prevents RAGE–HMGB1 interactions which leads to suppression of cytokine production mediated by macrophages. Methotrexate in high dose therapy has been indicated to reduce proliferation of monocytes as well as decrease inflammatory cytokine levels. Special attention should be paid to administration of high-dose methotrexate. It is accessible, cost effective with good CNS penetration. The use of methotrexate in COVID-19 cases with cytokine storm seems to be an appropriate option. However, this should be evaluated in clinical trials. Management of COVID-19 patients with a combination of recently approved remdesivir with an anti-inflammatory agent will possibly increase treatment efficiency.

Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARBs)

ACE2 as the receptor of SARS-CoV-2 is a significant component of the renin-angiotensin system (RAS). ACEI/ARBs are used primarily for the treatment of individuals with cardiovascular comorbidities.

On the one hand, overregulation of ACE2 can have a potential role in the increased risk of pulmonary infection. As mentioned above, SARS-CoV-2 uses the receptor ACE2 for entry into the target cells. It has been reported that both ACEI and ARBs could significantly upregulate mRNA expression of cardiac ACE2. Therefore, it has been hypothesized that the increased ACE2 expression may have an association with increased risk of severe course of COVID-19 cases.

On the other hand, ACE2 may play a protective role in both cardiovascular and pulmonary diseases. There is evidence that the ARBs have protective effects against viral spread of SARS-CoV-2. It has been observed that individuals using losartan or telmisartan as antihypertensives agents develop fewer attacks of cold and flu-like diseases. Both these drugs bind to the AT1 receptors stronger than valsartan. They can be administered either orally or in the form of a nasal spray. Improved survival has been observed following treatment with losartan in experimentally infected mice models with H5N1 influenza. Utilization of zinc supplement can also facilitate intracellular killing and phagocytosis. Therefore, ARBs (telmisartan and losartan) in therapeutic doses along with zinc can be used to control viral replication. Since the limited information, rapid clinical trials are required to investigate the use of losartan or telmisartan for inhibition of the viral entry into the host cell.

Collectively, the role of ACEIs and/or ARBs in facilitating SARS-CoV-2 entry and virus replication cannot be ignored. On the contrary, beneficial effect of ACEIs and/or ARBs in clinical outcomes after infection still remains unknown. Therefore, it seems that we are facing a double-edged sword depending on the disease phase. At the early stage of disease, increased expression of ACE2 may enhance infectivity and the use of ACEI/ARBs would be a potential risk factor, but once infection is established, ACE2 downregulation may lead to COVID-19 progression. Accordingly, upregulation of ACE2 in the acute phase of the disease may turn out to be advantageous.

There are several observational studies performed in different countries such as US, U, China, and Italy which were studied on confirmed COVID-19. None of these studies reported association between ACE inhibitors or ARBs and severity of COVID-19 infection. Moreover, there is no study described either benefits or harms of ACE inhibitors or ARBs as treatment for COVID-19 patients.

Nucleoside Analogs

Generally, nucleoside analogs are synthetic nucleosides that mimic their physiological counterparts. They inhibit the cellular nucleotide synthesis pathways and or viral replication through impairment DNA/RNA synthesis. Nucleoside analogs can target the RNA-dependent RNA polymerase that is necessary for viral RNA replication.

Favipiravir (T-705, Avigan, or favilavir) is a guanine analog with activity against various RNA viruses such as influenza, Ebola, yellow fever, and enterovirus. It is a small molecule with a plasma protein binding of about 60%. Therefore, it may appear in breast milk.
Favipiravir has shown effective antiviral activity in Vero E6 cells and has been suggested as a possible candidate for treatment of COVID-19. In combination with other antiviral agents such as IFN-α or baloxavir marboxil was used against SARS-CoV-2. An experimental treatment with favipiravir indicated its superior therapeutic effects against COVID-19 compared to lopinavir/ritonavir, concerning improvement of disease and viral clearance.

Ribavirin is another nucleotide guanine analog (guanosine analog) used for treatment against hepatitis C virus (HCV) and respiratory syncytial virus (RSV) infection as well as against SARS-CoV and MERS-CoV infections. In vitro studies have indicated synergistic effects of ribavirin with both leukocytic IFN-β and IFN-α against SARS-CoV. It may significantly impact the treatment of COVID-19 infection due to its availability and low cost. Ribavirin has shown adverse reactions including anemia and altered liver function. Therefore, special dosage consideration should be given.

Remdesivir (GS-5734) (CAS number: 1809249-37-3) is a novel small-molecule adenine nucleotide analog that was originally developed to treat Ebola virus. It is considered as a prodrug that is metabolized into its pharmacologically active form recognized as GS-441524. It can block replication of different coronaviruses such as SARS-CoV and MERS-CoV. Remdesivir has antiviral activity by inhibition of RdRp which cause interference with the RNA synthesis of virus. It is effective in the primary stage of infection and leads to a reduction of viral RNA levels. In vitro and in vivo studies have reported that the antiviral activity of remdesivir and IFN-β combination is superior compared to that of lopinavir/ritonavir-IFN-β against MERS-CoV. Remdesivir has also shown promising results in the treatment of SARS-CoV-2 infection. Currently there are several ongoing clinical trials on remdesivir in COVID-19 patients in numerous countries including France (NCT04314817, NCT04315948), USA (NCT04302766), Republic of Korea and Singapore (NCT04280705), and China (NCT04252664, NCT04257656).

Protease Inhibitors (PIs)

PIs are a class of antiviral medications that are mainly used for treatment of HIV and HCV. They selectively bind to viral proteases and block proteolytic cleavage of protein precursors, which leads to inhibition of infectivity and replication. Both lopinavir (ABT-378) and ritonavir (ABT-538) are protease inhibitors, used against HIV. The lopinavir/ritonavir combination is extensively used in the HIV management. Favorable therapeutic effects have been reported for lopinavir/ritonavir (Kaletra™) with ribavirin against SARS-CoV and MERS-CoV. This combination has been also suggested for COVID-19. In a previous study, following confirmed in vitro susceptibility of SARS-CoV to lopinavir/ritonavir, the clinical progress of SARS-CoV positive patients who were treated with a combination of ribavirin and lopinavir/ritonavir were compared with those treated with ribavirin only. The adverse outcome in the group who were treated with lopinavir/ritonavir was significantly lower than that of the other group. Furthermore, there is a case report of a patient with MERS-CoV infection who was successfully treated with triple combination of lopinavir/ritonavir, ribavirin and IFN-α and respiratory viral clearance achieved within six days.

Nelfinavir is also an antiretroviral drug that selectively inhibits the HIV protease. Its inhibitory effect has been shown for SARS-CoV suggesting its potential therapeutic effect for COVID-19. A previous study suggested that cytopathic effect of SARS-CoV infection could be inhibited by nelfinavir. The use of quantitative RT-PCR indicated that production of virions from Vero cells has been reduced by nelfinavir.

In a recent trial, oral lopinavir/ritonavir (400 mg/100 mg) twice daily for 14 days was prescribed for adults with severe COVID-19 infection. The results were compared to those who received standard treatment. The primary data from this trial indicated no advantage of using lopinavir/ritonavir treatment beyond standard care (ChiCTR2000029308). Determination of lopinavir/ritonavir effectiveness in COVID-19 patients needs to be further investigated. There are some clinical trials being conducted to assess the efficacy of lopinavir/ritonavir in combination with remdesivir and IFN-β-1a in COVID-19 cases in Hong Kong (NCT04276688), Republic of Korea (NCT04307693), China (NCT04255017, NCT04261907, NCT04286503), and in Europe (NCT04315948).

Type I IFNs

Immune intervention approaches to increase the immunity may help combat against viral infections. IFNs are the most broadly prescribed drugs with strong antiviral activities. IFN is a significant cytokine and represents one of the first lines of host defense against both DNA and RNA viruses. IFNs are classified into three groups, type I, II and III IFNs. Type I IFNs include structurally similar...
cytokines and comprise 13–14 subtypes of IFN-α together with IFN-β, IFN-ε, IFN-κ, IFN-ω, IFN-δ, IFN-ζ, and IFN-τ. In contrast, type II IFNs consist of IFN-γ. 124

Type I IFNs possess a wide range of biological activities and are the first cytokines produced during viral infections. They induce a wide range of proteins implicated in impairment of viral replication in targeted cells. Experiences from SARS-CoV have demonstrated the better antiviral activity of IFN-β compared to IFN-α. 125

A previous study evaluated antiviral effect of recombinant IFN-α and IFN-β against two clinical isolates of SARS-CoV (FFM-1 and Hong Kong) which were replicated in Caco2 and Vero cells. Their findings indicated that IFN-β was more effective than IFN-α in Caco2 cells. Moreover, in Vero cells, IFN-β was the most potent inhibitor of SARS-CoV and its selectivity index for SARS-CoV strain FFM-1 was 50 and 25 times higher than that of IFN-α and IFN-γ, respectively. 126

Nasal drops of IFN can maintain high levels of IFN-α in the nasal mucosa which may prevent the virus passing through the nasal mucosa. 123 A recent trial on the protective effect of recombinant human IFN-α (rhIFN-α) nasal drops against COVID-19 in HCWs reported a positive preventive effect of rhIFN-α nasal drops in susceptible healthy individuals against COVID-19 infection. 123

Moreover, a recent trial (phase I and II/not yet recruiting) has been registered to evaluate the adverse effects of rintatolimod and IFN-α-2b in management of cancer cases with mild or moderate COVID-19 infection (NCT04379518).

A recent study suggested that treatment with IFN-α2b considerably decreases viral clearance from the upper respiratory tract as well as decreases circulating levels of the inflammatory markers including IL-6 and CRP in COVID-19 patients. 127 According to WHO, IFN-α2b can be considered as a possible antiviral for the management of COVID-19. 128 Heberon® Alpha R is a human recombinant IFN-α2b which has indicated antiviral activities. 129 A multicenter prospective observational study in Cuba enrolled confirmed cases of COVID-19, suggested the therapeutic effects of IFNa-2b for COVID-19. It also showed that using Heberon® Alpha R may potentially improve the rates of recovery as well as case fatalities. 130

**Melatonin as a Potential Adjuvant Treatment**

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone with a variety of functions in health and has been effectively used to treat sleep disorders, atherosclerosis, respiratory diseases, and viral infections. The efficacy of melatonin has been recognized in experimental animal models and in human studies. Melatonin may have helpful adjuvant utility in treatment of COVID-19 induced pneumonia. 131 Excessive inflammation as a significant feature in COVID-19 patients can depress immune system and trigger cytokine storm. Due to anti-oxidative, anti-inflammatory, and immune enhancing properties, melatonin may have indirect antiviral effects. 132

A meta-analysis of randomized controlled trials revealed the association between melatonin supplementation and reduced level of TNF-α and IL-6. 133 Therefore, while there is no direct evidence of melatonin administration in COVID-19 patients, both anti-inflammatory role of melatonin and its safety profile may indicate its potential beneficial effect in COVID-19 patients. 134

**Monoclonal Antibodies**

Neutralizing monoclonal antibodies are an important part of protective immunity against several viral infections. 135 Some antigenic sites on surface proteins of a virus can be targeted by neutralizing monoclonal antibodies. 136 Therefore, this strategy can be considered as a potential option for prophylactic and therapeutic purposes. Moreover, effective monoclonal antibodies can be produced by immunization of humanized mice. 135 Neutralizing antibodies against coronaviruses mainly target S protein that facilitate virus entry into host cells through binding to the human ACE2 protein. 136

Effectiveness of monoclonal antibodies have been established in animal models for both MERS-CoV and SARS-CoV. 135 The efficiency of a high-affinity anti-S1 human monoclonal antibody (80R) against SARS-CoV infection through inhibition of syncytia formation between cells expressing the S protein and those expressing the SARS-CoV receptor ACE2 was described previously. 137

According to the former experience in the treatment of viral infections including SARS, MERS, influenza, and Ebola, mortality rate can be reduced by administration of stimulant plasma. 138,139 In passive immunization, antibodies specific for a certain epitope of pathogen can lead to a decreased viral proliferation and disease severity. 140 Due to the similarities between the SARS-CoV and SARS-CoV-2, some studies have repurposed the monoclonal antibodies against SARS-CoV for COVID-19 patients. 139

Currently, RBD on the S protein is the main target of neutralizing monoclonal antibodies against SARS-CoV-2. 141,142 The findings of recent studies show that B38, H4, as well as 47D11 are novel antibodies that have
indicated promising results in neutralizing the SARS-CoV-2 infection.\textsuperscript{143,144} The 47D11 antibody targets an epitope in the SARS2-S-S1B domain (residues 338–506) and neutralizes SARS-CoV and SARS-CoV-2 through an unknown mechanism.\textsuperscript{143} A recent study has isolated monoclonal antibodies from the B cells of COVID-19 recovered cases as well as from individuals infected with the SARS-CoV in 2003.\textsuperscript{135} A recent study on four human monoclonal antibodies (B38, B5, H2, and H4) isolated from a convalescent COVID-19 patient showed binding between studied antibodies and SARS-CoV-2 RBD. A competition assay to evaluate the ability of each antibody for inhibition of binding between RBD and ACE indicated that B38 and H4 antibodies completely blocked the binding of ACE-2 to RBD.\textsuperscript{144} These findings show that monoclonal antibodies have a potential therapeutic efficacy against COVID-19 infection. Several trials are evaluating the efficacy of various monoclonal antibodies for the treatment of hospitalized patients with COVID-19 (Table 1).

GM-CSF Inhibitors
GM-CSF is a cytokine with an important role in regulation of inflammation. In inflammatory conditions, the concentration of circulating GM-CSF is increased. Interaction between ligand and GM-CSF receptor-α can stimulate pro-inflammatory pathways and can lead to elevated production of pro-inflammatory cytokines such as TNF, IL1, IL6, IL-12, and IL23.\textsuperscript{145} It has been shown that GM-CSF+T cells are greatly associated with severity of COVID-19 infection.\textsuperscript{146} Therefore, clinical trials are initiated, evaluating whether the humanized monoclonal antibodies such as lenzilumab (class IgG1 κ) and mavrilimumab (human isoform IgG4), TJ 003234 (IgG1) that target GM-CSF can alleviate the cytokine release syndrome (CRS) and inhibit respiratory failure and/or death in COVID-19 patients\textsuperscript{147} (Table 1).

Lenzilumab is a recombinant monoclonal antibody (class IgG1 κ) with the potential to target GM-CSF.\textsuperscript{148} In a recent clinical study lenzilumab was used to treat hospitalized patients with severe COVID-19 pneumonia. Their results indicated clinical improvement in 92% of the patients (11 out of 12). In addition, cytokine analysis revealed a decrease in inflammatory myeloid cells following treatment with lenzilumab. Therefore, according to the results, they suggested that GM-CSF neutralization with lenzilumab was accompanied with improvement of clinical outcomes, oxygen requirement, and cytokine storm. Moreover, it was well tolerated with no adverse effects.\textsuperscript{148} In contrast, a case report study has described that despite the use of lenzilumab and hydroxychloroquine for treatment of a male with COVID-19 infection, clinical progression of symptoms continued. His subsequent treatment with tocilizumab showed significant clinical improvement within 48 hours. Consequently, they suggested the superiority of tocilizumab over lenzilumab in the management of CRS.\textsuperscript{149} Therefore, clinical trials should be conducted to assess the effect of lenzilumab on treatment and clinical outcome in patients with COVID-19 infection (Table 1).

IL-6 Inhibitors
It has been established that IL-6 has a crucial role in COVID-19 induced cytokine storms.\textsuperscript{150} IL-6 is a pro-inflammatory cytokine and is secreted by several cells including monocytes and lymphocytes. Increased serum levels of IL-6 has been correlated with the severe COVID-19 infection and its poor prognosis.\textsuperscript{151} IL-6 has several biological functions such as modulation of the host immune response and regulation of immune cell proliferation and differentiation and can lead to activation of Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway.\textsuperscript{152,153} Prompt synthesis of IL-6 plays a crucial role in host defense during infection; however, its excessive production can lead to disease pathology.\textsuperscript{154}

Inhibition of IL-6 is a therapeutic approach in numerous diseases such as rheumatoid arthritis with beneficial effects.\textsuperscript{155–157} Currently, IL-6 inhibitory agents are being evaluated for patients suffering from COVID-19.\textsuperscript{158} Therefore, several FDA approved anti-IL-6 agents such as tocilizumab, siltuximab, and sarilumab are currently being repurposed for treatment of COVID-19 infection.\textsuperscript{154} Siltuximab (Sylvant) is an FDA approved chimeric monoclonal antibody that binds to IL-6 and is used for the management of neoplastic diseases. Its treatment effects in COVID-19 patients with serious respiratory complications is under evaluation in a clinical trial (NCT04322188).

Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor (IL-6R) which can bind to both membrane-bound and soluble IL-6Rs and block IL-6-mediated signaling.\textsuperscript{159} It is an immunosuppressive drug and is used for treatment of rheumatoid arthritis. A retrospective observational study discussed the treatment response of tocilizumab therapy in COVID-19 cases.\textsuperscript{160} It has been suggested that tocilizumab is an effective treatment choice in critically ill COVID-19 patients with increased levels of IL-6.\textsuperscript{160,161} However, a recent study reported a potential association between administration of tocilizumab and increased
| Identifier Number | Brief Aim of Trial | Study Phase | Study Sponsor/ Country | Interventions |
|-------------------|-------------------|-------------|------------------------|---------------|
| NCT04425629       | To assess the safety, tolerability, and efficacy of anti-spike monoclonal antibodies for the treatment of ambulatory patients with COVID-19 | Phase 1 Phase 2 | Regeneron Pharmaceuticals/ France | Drug: REGN10933+REGN10987 Drug: placebo |
| NCT04346277       | Using IC14 to block CD14-mediated cellular activation in patients early in the development of ARDS. | - | Implicit Bioscience/ Italy | Biological: IC14 (A recombinant chimeric monoclonal antibody against CD14) |
| NCT04391309       | Assess IC14 in reducing the severity of respiratory disease in hospitalized COVID-19 patients | Phase 2 | Implicit Bioscience | Biological: IC14 Other: placebo |
| NCT04409509       | To evaluate CSL312 in COVID 19 | Phase 2 | CSL Behring/ United States | Biological: garadacimab, factor XIa antagonist monoclonal antibody Drug: placebo |
| NCT04351152       | To assess whether the use of lenzilumab + current standard of care (SOC) can alleviate the cytokine release syndrome (CRS) and inhibit development to respiratory failure and/or death in high risk COVID-19 patients | Phase 3 | Humanigen, Inc./ US | Biological: lenzilumab (anti-human GM-CS monoclonal antibody) Drug: standard of care |
| NCT04341116       | To assess the safety and efficacy of intravenous infusion of TJ003234 in cases with severe COVID-19 under supportive care, and to assess its effect on cytokines levels. | Phase 1 Phase 2 | I-Mab Biopharma Co. Ltd/US | Drug: TJ003234 (Anti-GM-CSF monoclonal antibody) Drug: placebo |
| NCT04433298       | To evaluate the efficacy and safety of intravenous pamrevlumab as compared to placebo in hospitalized cases of acute COVID-19. | Phase 2 | FibroGen | Drug: pamrevlumab (human recombinant monoclonal antibody against connective tissue growth factor (CTGF)) Drug: placebo |
| NCT04324021       | To assess the efficacy and safety of emapalumab or anakinra, vs standard of care (SoC) | Phase 2 Phase 3 | Swedish Orphan Biovitrum/Italy | Biological: emapalumab (anti-interferon-gamma (IFN-γ) monoclonal antibody) Biological: anakinra (recombinant form of a human receptor antagonist (IL-1ra)) |
| NCT04429529       | To assess safety of TY027 as a treatment for COVID-19 | Phase 1 | Tychan Pte Ltd/ Singapore | Biological: TY027 Other: 0.9% saline |
| NCT04386239       | To assess the efficacy and safety of sarilumab in COVID-19 patients | Early Phase 1 | ASST Fatebenefratelli Sacco | Drug: sarilumab (human monoclonal antibody against the interleukin-6 receptor) prefilled syringe |
| NCT04357808       | To assess the efficacy and safety of sarilumab for mild to moderate COVID-19 infection | Phase 2 | Maria del Rosario Garcia de Vicuña Pinedo/Spain | Drug: sarilumab Other: standard of care |
| NCT04324073       | To assess the therapeutic effect and tolerance of sarilumab in patients with moderate, severe pneumonia or critical COVID-19. | Phase 2 Phase 3 | Assistance Publique - Hôpitaux de Paris/ France | Drug: sarilumab |

(Continued)
Table 1 (Continued).

| Identifier Number | Brief Aim of Trial                                                                 | Study Phase | Study Sponsor/ Country                      | Interventions                                                                 |
|-------------------|----------------------------------------------------------------------------------|-------------|---------------------------------------------|------------------------------------------------------------------------------|
| NCT04351243       | To assess the efficacy and safety of gimsilumab in subjects with acute respiratory distress syndrome secondary to COVID-19. | Phase 2     | Kinevant Sciences GmbH/US                    | Drug: gimsilumab (anti-GM-CSF human monoclonal antibody)                      |
|                   |                                                                                  |             |                                             | Drug: placebo                                                                  |
| NCT04343651       | To assess the efficacy and safety of leronlimab for mild to moderate COVID-19 infection | Phase 2     | CytoDyn, Inc./US                            | Drug: leronlimab (humanized immunoglobulin (IgG4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195)) |
|                   |                                                                                  |             |                                             | Drug: placebos (700 mg)                                                       |
| NCT04347239       | To assess the efficacy and safety of leronlimab for patients with severe COVID-19 infection | Phase 2     | CytoDyn, Inc./US                            | Drug: leronlimab (700 mg)                                                    |
|                   |                                                                                  |             |                                             | Drug: placebos                                                                |
| NCT04305106       | To assess the efficacy and safety of bevacizumab for severe and critical COVID-19 patients. | NA          | Qilu Hospital of Shandong University/China | Drug: bevacizumab (humanized anti-VEGF monoclonal antibody)                    |
| NCT04413838       | To assess the efficiency and security of nivolumab therapy in obese individuals with COVID-19 infection | Phase 2     | Hospices Civils de Lyon/France              | Drug: nivolumab (fully human IgG4 (S228P) monoclonal antibody)                |
|                   |                                                                                  |             |                                             | Other: routine standard of care                                               |
| NCT04435184       | To assess the efficacy and safety of crizanlizumab in hospitalized patients with COVID-19 infection. | Phase 2     | Johns Hopkins University/US                 | Drug: crizanlizumab (anti-P-selectin monoclonal antibody)                      |
|                   |                                                                                  |             |                                             | Other: 0.9% saline                                                            |
| NCT04377750       | To assess the efficacy and safety of tocilizumab in the treatment of severe COVID-19 cases with suspected pulmonary hyperinflammation | Phase 3     | Hadassah Medical Organization/Israel        | Drug: tocilizumab (humanized monoclonal antibody against the IL-6 receptor)    |
| NCT04331808       | To assess the therapeutic effect and tolerance of tocilizumab in patients with moderate, severe pneumonia or critical pneumonia associated with COVID-19 infection | Phase 2     | Assistance Publique - Hôpitaux de Paris/ France | Drug: tocilizumab                                                          |
| NCT04330638       | To compare the efficacy of combinations of anti-IL drugs to best standard of care in treatment of patients with severe COVID-19 | Phase 3     | University Hospital, Ghent/ Belgium         | Other: usual care                                                             |
|                   |                                                                                  |             |                                             | Drug: anakinra                                                               |
|                   |                                                                                  |             |                                             | Drug: siltuximab                                                             |
|                   |                                                                                  |             |                                             | Drug: tocilizumab                                                            |
| NCT04341584       | To compare the efficacy of anakinra in patients with Covid-19 infection          | Phase 2     | Assistance Publique - Hôpitaux de Paris/ France | Drug: anakinra                                                             |
| NCT04397497       | To assess the efficacy and safety of mavrilimumab in hospitalized patients with severe COVID-19 infection and a hyper-inflammatory status. | Phase 2     | Ospedale San Raffaele/Italy                 | Drug: mavrilimumab (human monoclonal antibody against GM-CSF -R)             |
|                   |                                                                                  |             |                                             | Drug: placebo                                                                |
| NCT04390464       | To assess the potential treatment effect for COVID-19 disease (repurposed drugs)   | Phase 4     | Cambridge University Hospitals NHS Foundation Trust/ UK | Drug: ravulizumab (humanized monoclonal antibody against C5)                  |
|                   |                                                                                  |             |                                             | Drug: baricitinib                                                            |
|                   |                                                                                  |             |                                             | Other: standard of care                                                       |
secondary bacterial infections in critically ill COVID-19 cases. These controversial results highlight the urgent need for evaluation of immunosuppressive agents in randomized controlled trials to recognize their therapeutic role in COVID-19 infection.

Sarilumab (Kevzara) is also a fully human, monoclonal antibody and IL-6 receptor antagonist. It is FDA approved and is under evaluation of efficacy and safety for hospitalized patients with COVID-19 in a recent clinical trial (NCT04315298).

There are some other clinical trials evaluating therapeutic efficacy of anti-IL-6 agents together with other drugs such as hydroxychloroquine, azithromycin, and antivirals such as remdesivir enrolling diverse groups of the COVID-19 patients (Table 1).

### IL1-Inhibitors

IL-1 is one of the key mediators of innate immune system and inflammation. IL-1β can stimulate pro-inflammatory signaling in the respiratory tract.

Anakinra (Kineret) is a recombinant, nonglycosylated human IL-1 receptor antagonist (IL-1Ra). Anakinra has a very favorable safety profile and is mainly used for management of hyperinflammatory disorders such as Still’s disease, as well as in the treatment of cytokine storm syndromes. It has also been used against some severe viral infections including H1N1, EBV, and Ebola. A recent case report described a critical COVID-19 case who were successfully treated with anakinra. In addition, the use of anakinra in patients hospitalized with severe COVID-19 was evaluated in a prospective cohort study. Their findings indicated that anakinra has resulted in decreased necessity for invasive mechanical ventilation and reduced mortality. However, verification of its efficacy, dosing, and outcome measures will need controlled trials. As of now, there are some ongoing clinical trials using anakinra against COVID-19 infection (Table 1).

### TNF-α Inhibitors

TNF-α known as a major pro-inflammatory cytokine produced by stimulated macrophages, NK cells, T cells, and B cells. TNFα is implicated in primary inflammatory events and activates a series of several inflammatory molecules, including other cytokines, and chemokines, such as IL-8, CCL2, CCL3, and CCL4. TNF-α has an important role in the initiation and maintenance of CRS. Therefore, TNF-α can also be considered as a potential therapeutic target against COVID-19.

Adalimumab is a recombinant human IgG1 monoclonal antibody against human TNF-α which has been approved for management of rheumatoid arthritis. Currently, a trial has been registered in the Chinese Clinical Trial Registry (ChiCTR2000030089) to assess its efficacy and safety in patients with severe COVID-19 infection.

---

| Identifier Number | Brief Aim of Trial                                                                 | Study Phase | Study Sponsor/Country | Interventions                                                                 |
|-------------------|-----------------------------------------------------------------------------------|-------------|-----------------------|-------------------------------------------------------------------------------|
| NCT04369469       | To evaluate the efficacy and safety of intravenous ravulizumab compared to best supportive care in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome | Phase 3     | Alexion Pharmaceuticals | Biological: ravulizumab Other: best supportive care                          |
| NCT04322773       | To assess the effectiveness of IL-6 receptor inhibitors in the treatment of patients with severe COVID-19 infection. | Phase 2     | Marius Henriksen/Denmark | Drug: tocilizumab(RoActemra) iv (humanized monoclonal antibody against the IL-6 receptor) Drug: sarilumab (Kevzara) sc (humanized monoclonal antibody against the IL-6 receptor) Other: standard medical care |
| NCT04365153       | To assess whether early treatment with canakinumab inhibits progressive heart and respiratory failure in patients with COVID-19 infection | Phase 2     | The Cleveland Clinic/US | Drug: canakinumab (human monochlonal anti-IL-1β antibody) injection 600 mg Drug: canakinumab Injection 300 mg Drug: placebos                                                                 |
Convalescent Plasma

Most of the cases that recovered from COVID-19 infection show humoral and cellular immune responses against SARS-CoV-2. Therefore, some research groups have measured SARS-CoV-2 neutralizing antibody titers in the convalescent plasma.\(^{135}\) Recently, convalescent plasma has been extensively suggested for COVID-19. However, the effect of convalescent plasma cannot be differentiated from the effects of patient comorbidities, disease severity, or effect of other treatments.\(^{172}\) It has previously been used for treatment of some diseases including polio, measles, mumps as well as outbreaks of respiratory infections similar to COVID-19 such as H1N1 influenza, SARS, and MERS.\(^{173-175}\)

According to FDA, antibody-rich plasma from COVID-19 survivors might be effective against the infection.\(^{176}\)

A previous study reported on three HCWs infected with SARS-CoV who were successfully treated with convalescent plasma transfusion. A reduction of viral load was observed and all cases survived.\(^{173}\) Another study reported reduced viral load in majority of the patients with Ebola virus disease immediately after initiation of brincidofovir and convalescent plasma therapy.\(^{177}\) Moreover, potential efficiency of convalescent plasma therapy for clinical improvements of patients infected with MERS-CoV was revealed previously.\(^{174}\) The promising use of convalescent plasma therapy for influenza A (H5N1) infection was also described previously. The nonresponder patients to oseltamivir treatment alone fully recovered by using a combination of oseltamivir with convalescent plasma therapy. The viral loads decreased within eight hours of transfusion.\(^{175}\) Patients recovered from COVID-19 with a high neutralizing antibody titer are considered to be the eligible donors. Based on the preliminary results of a trial, convalescent plasma therapy can be a promising option for severe COVID-19 patients. They have reported that one dose of convalescent plasma with a high concentration of neutralizing antibodies can lead to a viral load reduction and tends to improve clinical outcomes.\(^{178}\) However, randomized clinical studies are required to investigate the optimal dose and treatment time point.\(^{178}\)

In the largest current study, the safety of convalescent plasma was explored in 5000 hospitalized critically ill COVID-19 patients.\(^{179}\) They have reported less than 1% severe adverse effects and 14.9% mortality rate in seven days, which is consistent with the deadly nature of COVID-19. Therefore, they have suggested that transfusion of convalescent plasma is harmless in hospitalized COVID-19 cases.\(^{179}\) Another recent study reported the outcomes of convalescent plasma transfusion in patients with severe COVID-19 infection. They have reported its useful therapeutic effects, especially in nonintubated patients.\(^{180}\) There are some limitations for using convalescent plasma therapy such as the difficulties in collection and possibility of contamination with infectious agents, transfusion-associated circulatory overload (TACO), adverse reactions to transfusion, and variation of neutralizing antibody responses.\(^{135}\)

Vitamin D

Vitamin D is a fat-soluble vitamin required for regulation of calcium and phosphate levels.\(^{181}\) SARS-CoV-2 uses ACE2 as a functional receptor for entry into target cells.\(^{182}\) In addition, downmodulation of ACE2 in the pulmonary tissues due to the infection with SARS-CoV-2 leads to severe acute respiratory failure.\(^{183}\) Downmodulation of alveolar ACE2 result in decreased angiotensin II level which causes its increased level and increased alveolar permeability and lung injury.\(^{184}\) Vitamin D3 is able to increase the ACE2 expression in several tissues including lung microvascular endothelial cells.\(^{185,186}\)

Elevated number of cell-bound ACE2s may function as a double-edged sword. On the one hand an increased number of ACE2 means an increased number of receptors for SARS-CoV-2 to enter the host cell. On the other hand these excessive ACE2s can competitively bind with the virus and neutralize it. Moreover, excessive ACE2 can protect the lung from injury through negative regulation of the RAS.\(^{187,188}\) However, vitamin D3 also plays an important role in innate and adaptive immune responses.\(^{184}\) It has immunomodulatory effects such as downregulation of pro-inflammatory cytokines.\(^{189-192}\) It has an important role in inhibiting the cytokine storm.\(^{193}\) Vitamin D deficiency has been correlated with greater susceptibility to viral infections.\(^{194}\) Therefore, it has been hypothesized that supplementation with vitamin D may reduce the severity of COVID-19 infection.\(^{195}\) It has been recognized that a number of immune cells express the vitamin D receptor (VDR). Several immune cells including macrophages, monocytes, dendritic cells, T cells, and B cells can convert 25-hydroxyvitamin D into its biologically active form 1,25-dihydroxyvitamin D (1,25-(OH)\(_2\)D). Binding of 1,25(OH)\(_2\)D to VDR promotes the expression of numerous genes, including cytokine-related genes.\(^{196}\)

Both pro-inflammatory and anti-inflammatory cytokines are produced by innate immune system in COVID-19 cases.\(^{11}\) The production of Th1 cytokines including IFN-\(\gamma\) and TNF-\(\alpha\) can be inhibited by vitamin D.\(^{197}\)
Furthermore, vitamin D supplementation can lead to decreased expression of macrophage mediated pro-inflammatory cytokines and elevated anti-inflammatory cytokines. The protective effect of sufficient vitamin D levels against RSV and influenza infections has been indicated previously. Decrease of serum 25-hydroxy levels with age may be attributed to higher case fatality rates (CFRs) in older COVID-19 patients. In addition, vitamin D deficiency is more frequent in countries with high geographic latitudes. Lack of memory B cells and atypical innate immune response can result in over activation of adaptive immune system in older individuals, which is followed by cytokine storm as seen in COVID-19 cases. A recent study reported the highest age-specific CFR due to COVID-19 in Spain, France, and Italy where vitamin D deficiency is more frequent than other countries (mean 25OHD concentration <0.25 ng/L). Therefore, supplementation with vitamin D may play a role in prevention of infection as well as improve the disease outcomes. Further studies are required to explore the whether 25-hydroxyvitamin D (25(OH)D) levels are associated with prevention and treatment of COVID-19. There are several clinical trials registered in clinicaltrial.gov that are investigating whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk of COVID-19 infection (for instance: NCT04394390, NCT04411446, NCT04385940, NCT04334005, NCT04386044, NCT04363840).

Vaccination

Vaccination may offer the best choice for COVID-19 control. Epitopes, mRNA, and S protein-RBD structure-based vaccines have been broadly suggested. Precise recognition of virus surface proteins and the host receptors is essential for understanding of cross-species transmission as well as for the establishment of animal models for vaccine development. Since the S protein is the major inducer of neutralizing antibodies, most of the vaccines being developed for coronaviruses target this protein. Various vaccines have been evaluated based on S protein including full-length and recombinant S protein vaccines, viral vector-based vaccine, DNA-based vaccine, and RBD protein-based vaccines.

There are several challenges in developing an effective vaccine for coronavirus infections including: lack of appropriate animal models that resemble human infection, clinical trials in humans are expensive to perform. Moreover, due to the great diversity in antigenic variants, antibody-mediated protective immunity against coronaviruses does not persist for very long. Human ACE2 transgenic mouse and rhesus monkey models have been used for vaccine development, and some clinical trials are in progress for SARS-CoV-2 vaccines.

Whole Virus Vaccines

Classic methods for viral vaccinations involve taking a live-attenuated or inactive whole virus. Whole virus vaccines have been shown to be inherently immunogenic and also have ability of toll-like receptors (TLRs) stimulation. A live influenza vaccine that expresses SARS-CoV-2 proteins has been developed by researchers at the University of Hong Kong. Moreover, Codagenix Inc. has established a “codon deoptimization” technology to attenuate viruses and is currently exploring the SARS-CoV-2 vaccine strategies.

Recombinant Subunit Vaccine

Generally, subunit-based vaccines are safer with fewer side effects than the other types of vaccines. They stimulate the immune system without introducing infectious viruses. Studies have reported increased T cell immune responses and production of high titer neutralizing antibodies in vivo due to subunit vaccines. The S protein contains three receptor-binding S1 heads and a trimeric S2 stalk. A recombinant subunit vaccine-based on the trimeric S protein is under preclinical test. Recently, The University of Queensland is developing subunit-based vaccines using the “molecular clamp”. A molecular clamp is a polypeptide used to stabilize the shape of proteins in experimental vaccines to improve recognition of the correct antigen, resulting stronger immune responses. The RBD of S protein plays a key role in interaction with the ACE2 as well as in the induction of neutralizing antibody against the virus. Therefore, RBD is being used in development of SARS-CoV-2 subunit vaccines.

DNA Vaccines

DNA vaccines as the third generation vaccines represent a novel approach. They contain DNA encoding particular antigens from a pathogen. The DNA is directly injected into the body and induces adaptive immune responses. Currently, different methods such as electroporation as a vaccine delivery system and addition of adjuvant to enhance the immune responses have been established to improve the efficiency of vaccines. Inovio Pharmaceuticals has announced its collaboration with Beijing Advaccine.
Biotechnologists have initiated a preclinical trial for COVID-19 DNA Vaccine INO-4800 development.\textsuperscript{219}

mRNA Vaccines

During the last two decades, mRNA vaccines have been developed for prophylactic and therapeutic purposes. Preclinical and clinical trials have revealed that mRNA-based vaccines elicit a safe and long-lasting immune response both in animal models and in humans. mRNA-based vaccines consist of mRNAs encoding a diseasespecific antigen being translated by the host machinery. These types of vaccines are unable to integrate into the host genome and can also produce multimeric antigens. Therefore, mRNA vaccines are superior to conventional vaccines in terms of safety and immune responses.\textsuperscript{220,221} A phase 1 clinical trial has been started for mRNA-1273, an mRNA vaccine, encoding a stable form of the SARS-CoV-2 protein of spike protein. In silico design of vaccine immunogens would allow its rapid production and efficacy evaluation.\textsuperscript{222}

Other Vaccine Approaches

A COVID-19 vaccine is being developed using Hyleukin-7 platform technology (IL-7 fused to hyFc) to enhance the immune responses. Hyleukin-7 is designed to hybridize IgD and IgG4 to generate longer-lasting and more effective Fc fusion proteins. Improved vaccine efficacy in influenza A virus infection model has been reported by Genexine Inc. Fc-fused IL-7 has resulted the accumulation of pulmonary T cells as well as increased plasmacytoid dendritic cells.\textsuperscript{222}

Bacillus Calmette–Guérin (BCG) Vaccine

In spite of global strict containment measures to combat the COVID-19 pandemic, increasing number of cases continue, especially in the US and Europe.\textsuperscript{223} There is a great variance in fatality rates across the world.\textsuperscript{224} For instance, studies from East Asian countries have reported lower incidence and case fatality rate due to COVID-19 infection.\textsuperscript{225}

\textit{Mycobacterium bovis} BCG vaccine is one of the most widely used vaccines worldwide. The main use of this vaccine is for vaccination against disseminated forms of tuberculosis in children. After introduction of BCG, studies revealed the decreased mortality independent of tuberculosis among vaccinated children.\textsuperscript{226} Some clinical evidence supports a role of BCG vaccination in nontargeted protective effects against viral infections. Several studies have demonstrated the effect of BCG vaccination on the reduction of acute lower respiratory tract infections.\textsuperscript{227,228} A study in Guinea-Bissau showed that BCG reduced the incidence of respiratory syncytial virus infection, which may support this hypothesis.\textsuperscript{229} Moreover, ecological studies have reported lower mortality due to COVID-19 infection in countries with mandatory BCG vaccination policies than other countries.\textsuperscript{230–232} However, there are several biases that should be considered. For instance, genetic diversity and polymorphism in population structure across regions, dissimilarities in detection and reports of infected cases, and different intervention policies used in different locations.\textsuperscript{223} Due to the controversial reports about the protective role of BCG vaccination against COVID-19 infection, a recent epidemiological study was conducted on a global scale using linear and nonlinear statistical methods. This study suggested a significant association between COVID-19 distribution and mortality rate with BCG vaccination.\textsuperscript{224} Furthermore, in another recent study used linear mixed models analysis indicated that mandated BCG vaccination policies significantly affect the mortality rate of COVID-19 infection.\textsuperscript{223} The association between BCG immunization and decreased spread and severity of the COVID-19 pandemic has also been reported in some other studies.\textsuperscript{234–236}

Moreover, effectiveness of BCG as nonspecific immunotherapy against virus-mediated clinical conditions has been previously indicated.\textsuperscript{237} Two recent studies have suggested an association between the BCG vaccination and reduced morbidity and mortality due to COVID-19.\textsuperscript{232,234} Moreover, an unpublished study compared COVID-19 fatality rates between countries with high disease burden and those with BCG revaccination policies. They have found significant differences in the COVID-19 fatality rates between the two groups of countries. The finding supports the possible protective role of BCG vaccination against COVID-19.\textsuperscript{234} Based on promising research it has been concluded that the BCG vaccination has beneficial off-target effects. However, there are some controversial studies about the effectiveness of BCG vaccination in induction of heterologous immunity. A randomized clinical multicenter trial reported that BCG vaccination has no effect on hospitalization rate of Danish children up to the age of 15 months.\textsuperscript{238} Furthermore, it appears that protective effect of BCG vaccine disappears with time. A previous study established no cross protection between BCG and the SARS-CoV.\textsuperscript{239,240}
Table 2: The Clinical Trials to Evaluate Whether Vaccination has any Effect on Prevention and/or Clinical Progression of COVID-19 Infection

| Identifier Number | Aim/Study Population                                                                 | Phase | Sponsor/Country                                  | Intervention/Treatment                        |
|-------------------|--------------------------------------------------------------------------------------|-------|-------------------------------------------------|-----------------------------------------------|
| NCT04435379       | To assess whether vaccination of elderly with VPM1002 could decrease hospital admissions and/or severe respiratory infectious diseases | Phase 3 | Vakzine Projekt Management GmbH/Germany          | Biological: VPM1002 Biological: placebo       |
| NCT04387409       | To assess whether vaccination of health-care professionals with VPM1002 could decrease the number of days absent from work due to respiratory disease | Phase 3 | Vakzine Projekt Management GmbH/Germany          | Biological: VPM1002 Biological: placebo       |
| NCT04348370       | To assess the efficacy of BCG vaccine for HCWs                                       | Phase 4 | Texas A&M University/United States               | Biological: BCG vaccine Biological: placebo   |
| NCT04373291       | To assess protective effect BCG vaccine in HCWs against COVID-19                      | Phase 3 | Bandim Health Project                            | Biological: BCG-Denmark Biological: saline    |
| NCT04384549       | To assess efficacy of BCG vaccine in the prevention of COVID-19 in HCWs              | Phase 3 | Assistance Publique - Hôpitaux de Paris/France  | Biological: BCG vaccine Biological: placebo   |
| NCT04414267       | To validate whether vaccination of individuals susceptible to COVID-19 with BCG vaccine can reduce their disease susceptibility (using both clinical and immunological criteria) | Phase 4 | Hellenic Institute for the Study of Sepsis/Greece | Biological: BCG vaccine Biological: placebo   |
| NCT04369794       | To assess the effect of former (the titer of anti-BCG IFN-γ) or recent BCG exposure (boost with intradermal vaccine) on clinical progression of disease | Phase 4 | University of Campinas/Brazil                    | Biological: BCG vaccine Biological: placebo   |
| NCT04327206       | To assess the effect BCG vaccination in protection of HCWs following against COVID-19 | Phase 3 | Murdoch Childrens Research Institute/Australia   | Biological: BCG vaccine Drug: placebo 0.9% NaCl|
| NCT04347876       | To assess whether previous BCG vaccination may modify the prognosis in COVID-19 positive cases | Observational | Assiut University/ Egypt                          | Diagnostic test: tuberculin test               |
| NCT04417335       | To assess the whether BCG vaccine can decrease hospital admission and improve the clinical course of COVID-19 infection in elderly individuals (≥60 years old). | Phase 4 | Radboud University/ Netherlands                  | Biological: BCG vaccine Biological: placebo   |
| NCT04350931       | To assess whether previous BCG vaccination can be used as immune-propylaxis among Egyptian HCWs against COVID-19 infection | Phase 3 | Ain Shams University/Egypt                       | Biological: intradermal injection of BCG vaccine Other: placebo |
| NCT04379336       | To assess whether BCG vaccine can decrease morbidity and mortality in HCWs exposed to SARS-CoV-2 | Phase 3 | TASK Applied Science/South Africa                | Biological: BCG Other: placebo                |
| NCT04362124       | To assess if BCG vaccination in HCWs can decrease the severity of COVID-19 Infection | Phase 3 | Universidad de Antioquia/ Colombia               | Biological: BCG vaccine Biological: placebo   |
| NCT04328441       | To reduce absenteeism among HCWs with direct patient contacts during the epidemic phase of COVID-19. Secondary objective: to reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of COVID-19. | Phase 3 | UMC Utrecht/Netherlands                          | Biological: BCG vaccine Biological: placebo   |

Abbreviations: HCWs, health-care workers; BCG, Bacillus Calmette–Guérin.
There are some potential confounders that may affect interpretation of correlation between BCG vaccination and COVID-19 related mortality. These include the possible underreporting as well as lower competence for SARS-COV-2 testing in low income countries. Therefore, randomized controlled trials are required to investigate whether BCG vaccination can induce trained immunity and protect against COVID-19. It is rational to suggest that these should first be initiated in high risk populations including HCWs as well as older individuals. Currently, trials have just begun in some countries such as the Netherlands, Australia, Greece, Britain, Germany, Denmark, and the US to investigate its potential protective effect against SARS-CoV-2 infection. There are some ongoing trials to explore the possible effects of vaccination in hospital staff.

However, strategies for immunity induction for protection purposes against SARS-CoV-2 infection may not be limited to BCG. For instance, VPM1002 vaccine (Vakzine Projekt Management) which is a novel genetically modified BCG vaccine and is being considered for clinical trials to assess its effectiveness against SARS-CoV-2 infections (Table 2).

A previous study has reviewed the molecular mechanism of nonspecific effects of BCG vaccine against viral infections. The epigenetic reprogramming of monocytes known as trained immunity is recommended as a potential reason for nonspecific effects of BCG. In a previous study, autophagy was recognized as a key component of trained immunity.

### Conclusion

The knowledge about this novel virus is still limited and the treatment options or vaccination are under assessment. SARS-CoV and MERS-CoV outbreaks have provided comprehensive insights into how to fight the SARS-CoV-2 pandemic. As of now, no vaccine or antiviral drug is available for COVID-19. What we can do currently is take measures to reduce the spread of COVID-19. Based on former experience in management of MERS and SARS infections, the WHO recommends infection control interventions to decrease the risk of transmission of infections. Implementation of control measures should be directed at limiting the possible sources of infection to prevent the risk of disease transmission in the absence of effective treatments. In addition, the asymptomatic spreaders also need to be focused.

### Abbreviations

ARDS, acute respiratory distress syndrome; ACE2, angiotensin-converting enzyme 2; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BCG, Bacillus Calmette–Guérin; CFRs, case fatality rates; COVID-19, coronavirus disease COVID-19; CLPro; 3CLp, chymotrypsin-like protease; CRP, C-reactive protein; cAMP, cyclic adenosine monophosphate; CRS, cytokine release syndrome; FGF, fibroblast growth factors; GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; GGO, ground glass opacity; HCWs, healthcare workers; HCV, hepatitis C virus; HMGB1, high-mobility group box 1; IFNγ, interferon gamma; JAK, Janus kinase; JAK-STAT, Janus kinase-signal transducer and activator of transcription; MIP, macrophage inflammatory proteins; MERS, Middle East respiratory syndrome; MCP-1, monocyte chemoattractant protein-1; NK, natural killer cells; NSAID, non-steroidal anti-inflammatory drugs; PLpro, papain-like protease; PDE4, phosphodiesterase 4; PDGF, platelet-derived growth factor; Pls, protease Inhibitors; RBD, receptor-binding domain; RAS, renin-angiotensin system; RSV, respiratory syncytial virus; RdRp, RNA-dependent RNA polymerase; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; The Food and Drug Administration; TLRs, toll-like receptors; TACO, transfusion-associated circulatory overload; TNF-α, tumor necrosis factor alpha.

### Acknowledgments

This research has been supported by Tehran University of Medical Sciences, Tehran, Iran.

### Disclosure

The author declares no conflicts of interest.

### References

1. Sun PLX, Xu C, Sun W, Pan B, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548–551. doi:10.1002/jmv.25722
2. Qun LMM, Xuhua G, Peng W, Xiaoye Wang MPH. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med. 2020.
3. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Rev. 2020;7(6):1012–1023. doi:10.1093/nsr/nwaa036
4. Belouzard S, Millet JK, Lecita BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Virus. 2012;4(6):1011–1033. doi:10.3390/v4061011
5. Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCoV. MedRxiv. 2020.

6. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–e18. doi:10.1016/j.jinf.2020.03.005

7. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454. doi:10.1038/s41418-020-0530-3

8. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X

9. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244

10. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032

11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5

12. Lee PI, Hu YL, Chen PY, Huang YC, Hsuhe PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53(3):371–372. doi:10.1016/j.jmii.2020.02.011

13. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.

14. Nickbach S, Mavir C, Mathews L, et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci U S A. 2019;116(52):27142–27150. doi:10.1073/pnas.1911083116

15. Uhlen H, Karlsson MJ, Zhong W, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science. 2019;366(6472):6472. doi:10.1126/science.aaz9198

16. Bhadra S, Jiang YS, Kumar MR, Johnson RF, Hensley LE, Ellington AD. Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV). PloS One. 2015;10(4):e0123126. doi:10.1371/journal.pone.0123126

17. Chan JF, Choi GK, Tsang AK, et al. Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses. J Clin Microbiol. 2015;53(8):2722–2726. doi:10.1128/JCM.01224-15

18. Huang P, Wang H, Cao Z, et al. A Rapid and Specific Assay for the Detection of MERS-CoV. Front Microbiol. 2018;9:1101. doi:10.3389/fmicb.2018.01101

19. Lee SH, Bae K-Y, Kim YH, Choi YK, Song MS, Ahn JY. One-pot reverse transcription loop-mediated isothermal amplification (RT-LAMP) for Detecting MERS-CoV. Front Microbiol. 2016;7:2166.

20. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa344

21. Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444–448. doi:10.1126/science.aas8836

22. Wang J, Du G. COVID-19 may transmit through aerosol. Ir J Med Sci. 2020;1–2.

23. Kanne JP. Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China. Key Points for the Radiologist. Radiological Society of North America; 2020.

24. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585

25. Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575. doi:10.3390/jcm9020575

26. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020.

27. Tobasz M, Qashqary M, Al-Dahery N, et al. Therapeutic management of patients with COVID-19: a systematic review. Infect Drug Resist. 2020;2020;23():100061.

28. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7

29. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020. doi:10.1016/j.jmii.2020.05.013

30. Lai -C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924

31. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71. doi:10.5582/ bst.2020.01020

32. Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [published online February 4, 2020]. Cell Res. 2020;30:269.

33. De Savi C, Hughes DL, Kværner L. Quest for a COVID-19 Cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev. 2020;24(6):940–976. doi:10.1021/op500233n

34. Liu C, Zhou Q, Li Y, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Sci. 2020;6(3):315–331. doi:10.1021/acscentsci.0c00272

35. Sandra S, Bart P, Vasilios P, Christos P, Mihael P. Direct ACE2-Spike RBD Binding Disruption with Small Molecules: A Strategy for COVID-19 Treatment. 2020.

36. Sachin P, Jeremy H, Pedro JB, et al. Drug repurposing for covid-19: discovery of potential small-molecule inhibitors of spike Protein-ACE2 receptor interaction through virtual screening and consensus scoring. 2020.

37. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e907. doi:10.1016/j.cell.2020.04.004

38. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132–140. doi:10.1016/j.antiviral.2008.10.009

39. Blaising J, Lévy PL, Polanyak SJ, Stanifer M, Boulant S, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2013;100(1):215–219. doi:10.1016/j.antiviral.2013.08.008

40. Blaising J, Polanyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94. doi:10.1016/j.antiviral.2014.04.006

41. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.

42. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613. doi:10.1016/j.jinf.2020.03.037
43. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934. doi:10.1001/jamainternmed.2020.0994
44. Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020.
45. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:10.1016/j.ebiom.2020.102763
46. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537
47. Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discovery. 2020;6(1):31. doi:10.1038/s41421-020-0168-9
48. Qin C, Zhou L, Hu Z, et al. Disregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
49. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Infect Infect. 2020;53(3):368–370. doi:10.1016/j.jmi.2020.03.005
50. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of COVID-19 infection: A report of five cases. Transl Res. 2020;220:1–13. doi:10.1016/j.trsl.2020.04.007
51. Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med. 2020;8(6):544–546. doi:10.1016/S2213-2600(20)30226-5
52. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.108393
53. Quartuccio L, Sonagli A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. medRxiv. 2020.
54. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331. doi:10.1016/S2555-8256(20)30127-2
55. Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci. 2020;116942. doi:10.1016/j.jns.2020.116942
56. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi:10.1016/S0140-6736(20)30317-2
57. Haberman R, Axelrad J, Chen A, et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. New Engl J Med. 2020;383(1):85–88. doi:10.1056/NEJMmc2009567
58. Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol Sci. 2020. doi:10.1016/j.tips.2020.06.007
59. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
78. Méhats C, Franco-Montoya ML, Boucherat O, et al. Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. PloS One. 2008;3(10):e3445. doi:10.1371/journal.pone.0003445

79. Sisson TH, Christensen PJ, Muraki Y, et al. Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiol Rep. 2018;6(12):e13753. doi:10.1484/phy.2.13753

80. Dalamaga M, Karampela I, Mantzoros CS. Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism. 2020;109:154282. doi:10.1016/j.metabol.2020.154282

81. Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F. CVID-19 pulmonary infection in erythromyeloid psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management. J Eur Acad Dermatol Venereol. 2020. doi:10.1111/jdv.16625

82. Oliisova OY, Anpilovga EM, Sivstunova DA. Apremilast as a potential treatment option for COVID-19: no symptoms of infection as a psoriatic patient. Dermatol Ther. 2020.e13668.

83. Frohman EM, Villemarette-Pittman NR, Cruz RA, et al. Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: an immune stabilization strategy for SARS-CoV-2 induced ‘PAAN’ attack. J Neurol Sci. 2020;116935.

84. Cribbs AP, Kennedy A, Penn H, et al. Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2015;67(5):1118–1192. doi:10.1002/art.39331

85. Kuroiwa Y, Takakusagi Y, Kusayanagi T, et al. Identiﬁcation and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PloS One. 2013;8(5):e63073. doi:10.1371/journal.pone.0063073

86. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology. 2003;42(10):1189–1196. doi:10.1093/rheumatology/kek323

87. Jean SS, Lee PI, Hsieh PR. Treatment options for COVID-19: the reality and challenges. J Microb Biol Infect. 2020;53(3):436–443. doi:10.1016/j.jmbi.2020.03.034

88. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-2 Receptor Blockers are not associated with severe SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. medRxiv. 2020.

89. Phadke M, Saunik S. Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartan in nCoV Wuhan Corona Virus infections—Novel mode of treatment. Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406. doi:10.1136/bmj.l6968

90. Prasad RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research. 2020;9:72. doi:10.12688/f1000research.22211.2

91. Gao H, Dai W, Zhao L, Min J, Wang F. The Role of Zinc and Zinc Homeostasis in Macrophage Function. J Immunol Res. 2018;2018:6872621. doi:10.1155/2018/6872621

92. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54–75 Years. medRxiv. 2020.

93. Bean D, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COV19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020.

94. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388. doi:10.1164/rcrm.202002.044550C

95. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv. 2020.

96. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi:10.1080/22221751.2020.1746200

97. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54–75 Years. medRxiv. 2020.

98. Phadke M, Saunik S. Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartan in nCoV Wuhan Corona Virus infections—Novel mode of treatment. Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406. doi:10.1136/bmj.l6968

99. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388. doi:10.1164/rcrm.202002.044550C

100. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv. 2020.

101. De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019;14(22):3962–3968. doi:10.1002/asia.201900841

102. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study. Engineering. 2020.

103. Ahn DG, Shin HJ, Kim MH, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–324. doi:10.4014/jmb.2003.03011

104. Zulma A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronavirus - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347. doi:10.1038/nrd.2015.37

105. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69–75. doi:10.1016/j.jcv.2004.03.003

106. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905–908. doi:10.1016/j.bbrc.2004.11.128

107. Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746. doi:10.1002/jmv.25798

108. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–46. doi:10.1016/j.ijid.2013.12.003
150. Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine Release Syndrome in COVID-19 Patients. A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. Int J Mol Sci. 2020;21(9):3330. doi:10.3390/ijms21093330

151. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. doi:10.1007/s00134-020-05991-x

152. Kang S, Tamaki T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007–1023. doi:10.1016/j.immuni.2019.03.026

153. Garbers C, Heinik S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutic approaches for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395–412. doi:10.1038/nrd.2018.45

154. Kato S, Kurzrock R. Repurposing Interleukin-6 Inhibitors to Combat COVID-19. J Immunother Precision Oncol. 2020;3(2):52–55.

155. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247–256. doi:10.1177/1759720X10378372

156. van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020;7(3):e209–e217. e209-e217. doi: 10.1016/S2352-3026(19)30257-1

157. Ascierto P, Fox B, Urba W. SITC statement on anti-IL-6/IL-6R for COVID-19. J Immunother Precision Oncol. 2020;3(1):e209–e217. doi:10.1016/j.immuni.2019.03.026

158. Dinarello CA, Simon A, van der Meer JW. Treating inﬂammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652. doi:10.1038/nrd3800

159. Rosé P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi:10.1182/blood.2018894168

160. van der Ven AJ, Netea MG, van der Meer JW, de Mast Q. Ebola Lymphohistiocytosis Syndrome. J Med Virol. 2019;92(17):2477. doi:10.1002/jmv.25262

161. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):1–5. doi:10.1186/s12967-020-02339-3

162. van Rhee F, Fayed L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28(23):3701–3708. doi:10.1200/JCO.2009.27.2377

163. Ascierto P, Fox B, Urba W. STIC statement on anti-IL-6/IL-6R for COVID-19. Society Immunother Cancer. 2020.

164. Kimmig LM, Wu D, Gold M, et al. IL6 inhibition in critically ill COVID-19 patients. Acta Clinica Bellica. 2020;64(4):564–570. doi:10.1182/blood.2018894618

165. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652. doi:10.1038/nrd3800

166. van der Ven AJ, Netea MG, van der Meer JW, de Mast Q. Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome. Front. Med. 2015;2:4. doi:10.3389/fmed.2015.00004

167. Filocamo G, Mangioni D, Tagliabue P, et al. Use of anakinra in severe COVID-19: a case report. Int J Infect Dis. 2020;96:607–609. doi:10.1016/j.ijid.2020.05.026

168. Huet T, Beausser H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400. e393-e400. doi:10.1016/S2665-9913(20)30164-8

169. Argawal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745–756. doi:10.1038/nri1184

170. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katzke MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. doi:10.1128/MMBR.05015-11

171. Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill. 2020;25:3.
189. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocytic/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–2135. doi:10.4049/jimmunol.1102412

190. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240–4270. doi:10.3390/nu7064240

191. Zdrengea MT, Makrianiotis H, Bagecan C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to viral respiratory infections. Rev Med Virol. 2017;27(1):1. doi:10.1002/rmv.1909

192. Arboleda JF, Fernandez GI, Urcuqui-Inchima S. Vitamin D-mediated attenuation of miR-155 in human macrophages infected with dengue virus: implications for the cytokine response. Infect Genet Evolution. 2019;69:12–21. doi:10.1016/j.meegde.2018.12.033

193. Khare D, Godbole NM, Pawar SD, et al. Calcitriol [1, 25(OH)2 D3] pre- and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. Eur J Nutr. 2013;52(4):1405–1415. doi:10.1007/s00394-012-0449-7

194. Beard JA, Bearden A, Striker R, Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194–200. doi:10.1016/j.jcv.2010.12.006

195. Razdan K, Singh K, Singh D. Vitamin D Levels and COVID-19 Susceptibility: is there any Correlation? Med Drug Discovery. 2020;7:100051. doi:10.1016/j.medidd.2020.100051

196. Takeuti FAC, Guimaraes FSF, Guimaraes PSA. Applications of vitamin D in sepsis prevention. Discov Med. 2018;25(140):291–297.

197. Sharifi V, Vahedi H, Nedjat S, Rahefie H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. APMS. 2019;127(10):681–687. doi:10.1111/apm.12982

198. Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020;12(1):1. doi:10.3390/nu12010236

199. Grant WB. Variations in vitamin D production could possibly explain the seasonality of childhood respiratory infections in Hawaii. Pediatr Infect Dis J. 2008;27(9):853. doi:10.1097/INF.0b013e3181817b8e1

200. Vásárhelyi B, Sátori A, Olajos F, Szabó A, Beko G. Low vitamin D levels among patients at Semmelweis University: retrospective analysis during a one-year period. Orv Hetil. 2011;152(32):1272–1277. doi:10.1556/OH.2011.29187

201. Novel, C.P.E.R.E. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003

202. Zhang YP, Daneshkhab A, Agraval V, Eshein A, Subramanian H, Roy HK, Backman V. The possible role of vitamin D in suppressing cytokine storm and associated mortality in COVID-19 patients. medRxiv. 2020.

203. Abdelmageed MI, Abdelmonem AH, Mustafa MI, et al. Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: an immunoinformatics approach. BioRxiv. 2020.

204. Xie L, Sun C, Luo C, et al. SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development. BioRxiv. 2020.

205. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236. doi:10.1038/nrmicro2090

206. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836–848. doi:10.1038/nrmicro3143

207. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERs, and other human coronavirus infections. Viruses. 2020;12(2):194. doi:10.3390/v12020194

208. China MoNDotPsRo. The Military Successfully Developed a Recombinant SARS-CoV-2 Vaccine. 2020.

209. Trial AMVeC. 2020. Available online: https://www.modernatx.com/modernaswork-potential-vaccine-against-covid-19 (accessed on 23 March 2020).

210. China coronavirus: hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China Morning Post. https://www.scmp.com/news/hong-kong/environment/article/3047956/china-coronavirus-hongkong-researchers-have-accessed 28 Feb 2020. 2020

211. Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;1–4.

212. Bisht H, Roberts A, Vogel L, Subbarao K, Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology. 2005;334(2):160–165. doi:10.1016/j.virol.2005.01.042

213. Okba NM, Raj VS, Haagmans BL. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr Opin Virol. 2017;23:49–58. doi:10.1016/j.coiviro.2017.03.007

214. Mukherjee L. Global efforts on vaccines for COVID-19: since, sooner or later, we all will catch the coronavirus. J Biosci. 2020;45(1):1. doi:10.1007/s12038-020-00040-7

215. Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed’. Science Alert 2020 https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed Accessed 28 Feb 2020. 2020

216. Zha N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017

217. Yang Z-Y, Kong W-P, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–564. doi:10.1038/nature02463

218. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421–429. doi:10.1016/j.coi.2011.03.008

219. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800 Available from http://irinovicomednews-andmedia/news/presse-release-details/2020/Inovio-Accelerates-imeline-for-COVID-19-DNA-VaccineINO-4800/default.aspx Accessed 03 Mar 2020. 2020

220. Li J, Zhang C, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594. doi:10.3389/fimmu.2019.00594

221. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines— a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261. doi:10.1038/nrd.2017.243

222. Sceo YB, Im SJ, Namkoong H, et al. Crucial roles of interleukin-7 in COVID-19 patients. medRxiv. 2020.

223. O’Neill LA, Netae MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020;20(6):335–337. doi:10.1038/s41577-020-0337-y

224. Ventura L, Vitali M, Spica VR. BCG vaccination and socioeconomic variables vs Covid-19 global features: clearing up a controversial issue. medRxiv. 2020.

225. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534. doi:10.1016/S1473-3099(20)30120-1
226. Moorlag S, Arts RJ, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478.

227. Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018;379(2):138–149. doi:10.1056/NEJMoa1714021

228. Wardhana DE, Mandang V, Mandang V, Jim E, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43(3):185–190.

229. Stensballe LG, Nante E, Jensen IP, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls: community based case–control study. Vaccine. 2005;23 (10):1251–1257. doi:10.1016/j.vaccine.2004.09.006

230. Gursel M, Gursel I. Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Med Hypotheses. 2020;109707.

231. Shet A, Ray D, Malavige N, Santosham M, Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. MedRxiv. 2020.

232. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv. 2020.

233. Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S. Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. MedRxiv. 2020.

234. Dayal D, Gupta S. Connecting BCG Vaccination and COVID-19: additional Data. MedRxiv. 2020.

235. Klinger D, Blass I, Rappoport N, Linial M. Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis. medRxiv. 2020.

236. Green CM, Fanucchi S, Fok ET, et al. COVID-19: A model correlating BCG vaccination to protection from mortality implicates trained immunity. MedRxiv. 2020.

237. Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable bacillus Calmette-Guérin. Pediatr Dermatol. 2013;30(1):60–63. doi:10.1111/j.1525-1470.2012.01848.x

238. Stensballe LG, Ravn H, Birk NM, et al. BCG Vaccination at birth and rate of hospitalization for infection until 15 months of age in Danish children: a randomized clinical multicenter trial. J Pediatric Infect Dis Soc. 2019;8(3):213–220. doi:10.1093/jpids/piy029

239. de Castro MJ, Pardo-Seco J, Martínón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis. 2015;60(11):1611–1619. doi:10.1093/cid/civ144

240. Yu Y, Jin H, Chen Z, et al. Children’s vaccines do not induce cross reactivity against SARS-CoV. J Clin Pathol. 2007;60 (2):208–211. doi:10.1136/jcp.2006.038893

241. Mogica JAP, Nava V, Torres J. COVID-19 Related Mortality and BCG Vaccination. medRxiv. 2020.

242. Moorlag S, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478. doi:10.1016/j.cmi.2019.04.020

243. Buffen K, Oosting M, Quintin J, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 2014;10(10): e1004485. doi:10.1371/journal.ppat.1004485